Seeking Alpha

Biogen Idec (BIIB +2.6%) moves up after saying it and Swedish Orphan Biovitrum released data...

Biogen Idec (BIIB +2.6%) moves up after saying it and Swedish Orphan Biovitrum released data that confirms the ability of its investigational recombinant factors VIII Fc fusion protein and IX Fc fusion protein to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia. Separately, Citigroup throws in the towel and ups the shares to Buy, saying the fundamentals are just too strong to look for any pullback opportunity to pick the shares up cheaper.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector